Indian contract development and manufacturing organization (CDMO) Shilpa Biologicals announced the commissioning of an antibody–drug conjugate (ADC) GMP manufacturing facility. According to the company, the facility in Dharwad, India, is fully operational, with GMP qualification protocols actively underway, positioning the firm for commercial readiness.